Macular epiretinal brachytherapy in treated age-related macular degeneration (meritage): Month 24 safety and efficacy results

Retina

Volumn 34, Issue 5, 2014, Pages 874-879

  Petrarca, Robert ^a,b   Dugel, Pravin U ^c   Bennett, Michael ^d   Barak, Adiel ^e   Weinberger, Dov ^f   Nau, Jeffrey ^g,h   Jackson, Timothy L ^a,b  

^a KING S COLLEGE HOSPITAL   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c RETINAL CONSULTANTS OF ARIZONA   (United States)

^d Retina Institute of Hawaii   (United States)

^e TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^f RABIN MEDICAL CENTER   (Israel)

^g NeoVista   (United States)

^h GENENTECH INC   (United States)

Author keywords

Epimacular brachytherapy; Neovascular age related macular degeneration; Radiation; Radiation retinopathy

Indexed keywords

RANIBIZUMAB; STRONTIUM 90; YTTRIUM 90; ANGIOGENESIS INHIBITOR; MONOCLONAL ANTIBODY; STRONTIUM; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN; YTTRIUM;

ADULT; AGED; ARTICLE; BRACHYTHERAPY; CANNULA; CILIARY DISK; CONTROLLED STUDY; DIABETIC RETINOPATHY; DRUG EFFICACY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OPTICAL COHERENCE TOMOGRAPHY; PATIENT SAFETY; PROSPECTIVE STUDY; RETINA MACULA AGE RELATED DEGENERATION; SURGICAL TECHNIQUE; TREATMENT OUTCOME; VISUAL ACUITY; VITRECTOMY; VITREOUS HEMORRHAGE; ADJUVANT THERAPY; ANTAGONISTS AND INHIBITORS; CHRONIC DISEASE; CLINICAL TRIAL; EPIRETINAL MEMBRANE; FLUORESCENCE ANGIOGRAPHY; INTERVENTION STUDY; INTRAVITREAL DRUG ADMINISTRATION; MIDDLE AGED; MULTICENTER STUDY; PATHOPHYSIOLOGY; PHYSIOLOGY; RADIATION DOSE; VERY ELDERLY; WET MACULAR DEGENERATION;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; BRACHYTHERAPY; CHRONIC DISEASE; EPIRETINAL MEMBRANE; FEMALE; FLUORESCEIN ANGIOGRAPHY; HUMANS; INTERVENTION STUDIES; INTRAVITREAL INJECTIONS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RADIOTHERAPY DOSAGE; RADIOTHERAPY, ADJUVANT; STRONTIUM RADIOISOTOPES; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY; WET MACULAR DEGENERATION; YTTRIUM RADIOISOTOPES;

EID: 84899985805     PISSN: 0275004X     EISSN: 15392864     Source Type: Journal    
DOI: 10.1097/IAE.0000000000000026     Document Type: Article

References (20)

1. Ferris FL III, Fine SL, Hyman L. Age-related macular degeneration and blindness due to neovascular maculopathy. Arch Ophthalmol 1984;102:1640-1642.
2. Petrarca R, Jackson T. Radiation therapy for neovascular agerelated macular degeneration. Clin Ophthalmol 2011;5:57-63.
3. Silva RA, Moshfeghi AA, Kaiser PK, et al. Radiation treatment for age-related macular degeneration. Semin Ophthalmol 2011; 26:121-130.
4. Petrarca R, Richardson M, Douri A, et al. Safety testing of epimacular brachytherapy with microperimetry and indocyanine green angiography: 12 month results. Retina 2013;33:1232-1240.
5. Ávila MP, Farah ME, Santos A, et al. Twelve-month short-term safety and visual-Acuity results from a multicentre prospective study of epiretinal strontium-90 brachytherapy with bevacizumab for the treatment of subfoveal choroidal neovascularisation secondary to age-related macular degeneration. Br J Ophthalmol 2009;93:305-309.
6. Avila MP, Farah ME, Santos A, et al. Twelve-month safety and visual acuity results from a feasibility study of intraocular, epiretinal radiation therapy for the treatment of subfoveal CNV secondary to AMD. Retina 2009;29:157-169.
7. Avila MP, Farah ME, Santos A, et al. Three-year safety and visual acuity results of epimacular 90 strontium/90 yttrium brachytherapy with bevacizumab for the treatment of subfoveal choroidal neovascularization secondary to age-related macular degeneration. Retina 2012;32:10-18.
8. Dugel P, Bebchuk J, Nau J, et al. Epimacular brachytherapy for neovascular age-related macular degeneration (CABERNET): a randomized, controlled trial. Ophthalmology 2013;120: 317-327.
9. Dugel P, Petrarca R, Bennett M, et al. Macular epiretinal brachytherapy in treated age-related macular degenation (MERITAGE Study): twelve-month safety and efficacy results. Ophthalmology 2012;119:1425-1431.
10. Petrarca R, Dugel P, Nau J, et al. Macular epiretinal brachytherapy in treated age-related macular degeneration (MERITAGE): month 12 optical coherence tomography and fluorescein angiography. Ophthalmology 2013;120:328-333.
11. Early Treatment Diabetic Retinopathy Study Research Group. Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Arch Ophthalmol 1985;103:1796-1806.
12. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006;355:1419-1431.
13. Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006;355:1432-1444.
14. Lux A, Llacer H, Heussen FMA, et al. Non-responders to bevacizumab (Avastin) therapy of choroidal neovascular lesions. Br J Ophthalmol 2007;91:1318-1322.
15. Forooghian F, Cukras C, Meyerle C, et al. Tachyphylaxis after intravitreal bevacizumab for age-related macular degeneration. Retina 2009;29:723-731.
16. Hwang JC, Del Priore LV, Freund KB, et al. Development of subretinal fibrosis after anti-VEGF treatment in neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging 2011;42:6-11.
17. Cho M, Barbazetto IA, Freund KB. Refractory neovascular age-related macular degeneration secondary to polypoidal choroidal vasculopathy. Am J Ophthalmol 2009;148:70-78. e71.
18. Jackson T, Donachie P, Sparrow J, et al. United Kingdom National Ophthalmology Database study of vitreoretinal surgery: report 1; case mix, complications, and cataract. Eye (Lond) 2013;27:644-651.
19. Gordon KB, Char DH, Sagerman RH. Late effects of radiation on the eye and ocular adnexa. Int J Radiat Oncol Biol Phys 1995;31:1123-1139.
20. Jackson TL, Dugel PU, Bebchuk JD, et al. Epimacular brachytherapy for neovascular age-related macular degeneration (CABERNET): fluorescein angiography and optical coherence tomography. Ophthalmology 2013;120:1597-1603.